View Older Stories View More Recent Stories
-
RMG Networks Raises $25 Million in Private Placement of Convertible Preferred Stock
-
Mad Catz (MCZ) Enters 8.98M Common, 4.49M Warrants Direct Offering
-
Mad CatzĀ® Announces $3.7 Million Registered Direct Offering
-
Concert Pharmaceuticals Announces Completion of Public Offering
-
GenVec (GNVC) FY14 Results Flat with Views; Hearing Loss Phase I Update Encouraging - Roth Capital
-
PRESERVATION I Study is Key Upcoming Milestone for BioLineRx (BLRX); Roth Affirms at 'Buy'
-
Can-Fite Bio Pharma's (CANF) CF101 Receives Additional Validation with Latest Agreement - Roth
-
Notable Analyst Rating Changes 3/23: (SPLS) (ELY) (NMM) Upgraded; (NVDA) (CCL) (SHW) Downgraded
-
UPDATE: Roth Capital Downgrades MEI Pharma (MEIP) to Neutral; Future of Pracinostat Now in Question
-
Bluebird Bio (BLUE) PT Raised to $145 at Roth Capital
-
Concert Pharma (CNCE) Prices 3.3M Common Stock Offering at $15.15/Share
-
Concert Pharmaceuticals Announces Pricing of Public Offering
-
Galena Biopharma Announces Closing of Public Offering of Common Stock and Warrants
-
Galena Biopharma Announces Closing of Public Offering of Common Stock and Warrants
-
MLP Benefit Likely $3 to $6/Share for Green Plains (GPRE); Roth Affirms at 'Buy'
-
Can-Fite BioPharma (CANF) Reaches Important Milestone; Psoriasis Data Expected Soon - Roth
-
Roth Capital Downgrades RSP Permian, Inc. (RSPP) to Neutral
-
Amid Plug Power's (PLUG) Achievements, More Gross Margin Improvement Needed; Roth Trims PT to $2.60
-
Roth Affirms Rexahn (RNN) at 'Buy' Following FY14 Results; Supinoxin, RX-3117 Remain in Focus
-
Roth Affirms Celldex (CLDX) at 'Focus Pick'; Solidifying Itself as Premier Cancer Immunotherapy Company
-
Roth Trims PT on Nuverra Environmental Solutions (NES) to $3.50; Asset, Labor Utilization Showing Improvement
-
UPDATE: Roth Capital Downgrades Dynamic Materials (BOOM) to Neutral
-
Roth Capital Reinstates Conatus Pharmaceuticals (CNAT) at Buy
-
Rexahn Pharma (RNN) Reports Wider Loss for 2014; Updates on Clinical Development Programs
-
Rexahn Pharmaceuticals Reports Fourth Quarter and Full-Year 2014 Financial Results and Pipeline Update
-
Roth Affirms Spectrum Pharma (SPPI) at 'Neutral'; Focus Remains on Pipeline Advancement
-
COSMIC-HF Phase 2 Reaches Important Milestone; Roth Affirms Cytokinetics (CYTK) at 'Buy'
-
JA Solar (JASO) Capacity Expansion Remains on Track; Roth Capital Affirms 'Buy' Rating
-
Galena Biopharma (GALE) Prices 24.4M Common, Warrants Offering at $1.56/Unit
-
Galena Biopharma Announces Pricing of Public Offering of Common Stock and Warrants
-
Galena Biopharma Announces Pricing of Public Offering of Common Stock and Warrants
-
Aeterna Zentaris Announces Closing of US$37 Million Public Offering of Common Shares and Warrants
-
Staffing 360 Solutions Hosts Presentation at the 27th Annual ROTH Conference Today at 8:00 am Pacific
-
SolarEdge Technologies (SEDG) Commences 7M Common IPO
-
SolarEdge Technologies, Inc. Announces the Lanuch of its Initial Public Offering
-
Unusual 11 Mid-Day Movers 3/10: (CASI) (REPH) (JOB) Higher; (NNBR) (IDT) (TITN) Lower
-
PlasmaTech Biopharmaceuticals To Present at 27th Annual ROTH Capital Partners Conference - NEW TIME SLOT
-
Xplore Announces Closing of Public Offering of 2,300,000 Shares Of Common Stock
-
IGI Laboratories To Present At 27th Annual ROTH Capital Conference On March 9, 2015
-
The Piacente Group Sponsors the ROTH Capital Partners 27th Annual OC Growth Stock Conference
-
Evolution Petroleum to Present at the 27th Annual Roth Capital Conference on March 10, 2015
-
AETI CEO to Present at ROTH Capital Partners 27th Annual Growth Stock Conference
-
Uranium Resources Announces Closing of Registered Direct Financing, Upcoming ROTH Conference Presentation and 2014 Financial Results Conference Call
-
Dynamic Materials (BOOM) Will Only Feel Pinch on Tax Line in Restatement; Roth Affirms at 'Buy'
-
Notable 52-Week Highs and Lows 3/6: (HBAN) (FL) (CLDN) High; (DAR) (CKP) Low
-
Notable Analyst Rating Changes 3/6: (CSIQ) (CG) (C) Upgraded; (HST) (ESL) (STT) Downgraded
-
Robust Plant Production Bolsters Pacific Ethanol's (PEIX) Q4 Results - Roth Capital
-
BioLineRx (BLRX) Prices 12.5M Public Offering at $2/ADS
-
Quantum Technologies to Present at the 27th Annual ROTH Conference
-
Canadian Solar (CSIQ) Q4 Results, Outlook Solid; Roth Trims FY15 Expectations on YieldCo Prep

